- Consensus Rating
- Moderate Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 20 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $69.25 (61.3% Upside)
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
More about Exact Sciences
Recent Analyst Ratings
